Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Open access

Abstract

BACKGROUND: The extent to which response and survival benefits with immunotherapy-based regimens persist informs optimal first-line treatment options. We provide long-term follow-up in patients with advanced renal cell carcinoma (aRCC) receiving first-line nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) in the phase 3 CheckMate 214 trial. Survival, response, and safety outcomes with NIVO+IPI versus SUN were assessed after a minimum of 42 months of follow-up. METHODS: Patients with aRCC were enrolled from October 16, 2014, through February 23, 2016. Patients stratified by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk and region were randomized to nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks for four doses, followed by nivolumab (3 mg/kg) every 2 weeks; or SUN (50 mg) once per day for 4 weeks (6-week cycle). Primary endpoints: overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) per independent radiology review committee in IMDC intermediate-risk/poor-risk patients. Secondary endpoints: OS, PFS, and ORR in the intention-to-treat (ITT) population and safety. Favorable-risk patient outcomes were exploratory. RESULTS: Among ITT patients, 550 were randomized to NIVO+IPI (425 intermediate/poor risk; 125 favorable risk) and 546 to SUN (422 intermediate/poor risk; 124 favorable risk). Among intermediate-risk/poor-risk patients, OS (HR, 0.66; 95% CI, 0.55-0.80) and PFS (HR, 0.75; 95% CI, 0.62-0.90) benefits were observed, and ORR was higher (42.1% vs 26.3%) with NIVO+IPI versus SUN. In ITT patients, both OS benefits (HR, 0.72; 95% CI, 0.61-0.86) and higher ORR (39.1% vs 32.6%) were observed with NIVO+IPI versus SUN. In favorable-risk patients, HR for death was 1.19 (95% CI, 0.77-1.85) and ORR was 28.8% with NIVO+IPI versus 54.0% with SUN. Duration of response was longer (HR, 0.46-0.54), and more patients achieved complete response (10.1%-12.8% vs 1.4%-5.6%) with NIVO+IPI versus SUN regardless of risk group. The incidence of treatment-related adverse events was consistent with previous reports. CONCLUSIONS: NIVO+IPI led to improved efficacy outcomes versus SUN in both intermediate-risk/poor-risk and ITT patients that were maintained through 42 months' minimum follow-up. A complete response rate >10% was achieved with NIVO+IPI regardless of risk category, with no new safety signals detected in either arm. These results support NIVO+IPI as a first-line treatment option with the potential for durable response. TRIAL REGISTRATION NUMBER: NCT02231749.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2020-000891

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Overall survival. (A) In intermediate-risk/poor-risk patients. (B) In intent-to-treat patients. (C) In favorable-risk patients. mOS, median overall survival; NE, not estimable; NIVO+IPI, nivolumab plus ipilimumab; NR, not reached; SUN, sunitinib.
Figure 1 Overall survival. (A) In intermediate-risk/poor-risk patients. (B) In intent-to-treat patients. (C) In favorable-risk patients. mOS, median overall survival; NE, not estimable; NIVO+IPI, nivolumab plus ipilimumab; NR, not reached; SUN, sunitinib.CC BY-NC · PubMed Central
Figure 2 Progression-free survival and duration of response per independent radiology review committee. (A, B) In intermediate-risk/poor-risk patients. (C, D) In intent-to-treat patients. (E, F) In favorable-risk patients. mDOR, median duration of response; mPFS, median progression-free survival; NE, not estimable; NIVO+IPI, nivolumab plus ipilimumab; NR, not reached; SUN, sunitinib.
Figure 2 Progression-free survival and duration of response per independent radiology review committee. (A, B) In intermediate-risk/poor-risk patients. (C, D) In intent-to-treat patients. (E, F) In favorable-risk patients. mDOR, median duration of response; mPFS, median progression-free survival; NE, not estimable; NIVO+IPI, nivolumab plus ipilimumab; NR, not reached; SUN, sunitinib.CC BY-NC · PubMed Central
Figure 3 Treatment-free interval and response outcomes in complete responders. (A) In intermediate-risk/poor-risk (top) and favorable-risk (bottom) patients in the NIVO+IPI arm. (B) In intermediate-risk/poor-risk (top) and favorable-risk (bottom) patients in the SUN arm. TFI was defined as the time between protocol therapy discontinuation until subsequent therapy initiation or last known date alive. Bar indicates time on treatment/TFI. Time zero corresponds to first treatment date. Of all-risk patients, 11 versus 6 received subsequent systemic therapy with NIVO+IPI versus SUN. These patients may have stopped therapy due to investigator-assessed progression or other protocol-specified reason such as toxicity (data not shown). The decision to start subsequent systemic therapy in either arm was made by the investigator based on expert opinion and treatment guidelines, and these data were not formally collected. ITT, intention-to-treat; NIVO+IPI, nivolumab plus ipilimumab; TFI, treatment-free interval in patients who are off study treatment.
Figure 3 Treatment-free interval and response outcomes in complete responders. (A) In intermediate-risk/poor-risk (top) and favorable-risk (bottom) patients in the NIVO+IPI arm. (B) In intermediate-risk/poor-risk (top) and favorable-risk (bottom) patients in the SUN arm. TFI was defined as the time between protocol therapy discontinuation until subsequent therapy initiation or last known date alive. Bar indicates time on treatment/TFI. Time zero corresponds to first treatment date. Of all-risk patients, 11 versus 6 received subsequent systemic therapy with NIVO+IPI versus SUN. These patients may have stopped therapy due to investigator-assessed progression or other protocol-specified reason such as toxicity (data not shown). The decision to start subsequent systemic therapy in either arm was made by the investigator based on expert opinion and treatment guidelines, and these data were not formally collected. ITT, intention-to-treat; NIVO+IPI, nivolumab plus ipilimumab; TFI, treatment-free interval in patients who are off study treatment.CC BY-NC · PubMed Central
Figure 4 Six-month landmark analysis of overall survival by best overall response per RECIST V.1.1 (per IRRC). (A) In the NIVO+IPI arm. (B) In the SUN arm. CR, complete response; IRRC, independent radiology review committee; NIVO+IPI, nivolumab plus ipilimumab; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; SUN, sunitinib.
Figure 4 Six-month landmark analysis of overall survival by best overall response per RECIST V.1.1 (per IRRC). (A) In the NIVO+IPI arm. (B) In the SUN arm. CR, complete response; IRRC, independent radiology review committee; NIVO+IPI, nivolumab plus ipilimumab; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; SUN, sunitinib.CC BY-NC · PubMed Central
Figure 5 Six-month landmark overall survival analyses in intent-to-treat patients with nivolumab plus ipilimumab. (A) Immune-related adverse events (irAEs), yes versus no. (B) Treatment-related adverse events (TRAEs) leading to discontinuation, yes versus no. Includes events reported between first dose and 30 days after last dose of study therapy. mOS, median overall survival; NE, not estimable; NR, not reached.
Figure 5 Six-month landmark overall survival analyses in intent-to-treat patients with nivolumab plus ipilimumab. (A) Immune-related adverse events (irAEs), yes versus no. (B) Treatment-related adverse events (TRAEs) leading to discontinuation, yes versus no. Includes events reported between first dose and 30 days after last dose of study therapy. mOS, median overall survival; NE, not estimable; NR, not reached.CC BY-NC · PubMed Central
Figure 6 Safety outcomes over time. (A) Treatment-related adverse events (AEs) over time by 6-month interval with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN). (B) Select treatment-related AEs over time by 6-month interval with NIVO+IPI. (C) Corticosteroid use over time with NIVO+IPI. aN=patients at risk at the beginning of each 6-month interval, and patients may be counted more than once across intervals. bIncidence of grade 3–4 treatment-related AEs in all intervals with NIVO+IPI after 24 months was ≤2.4%. cN=patients at risk at the beginning of each 6-month interval, and patients may be counted more than once across intervals. dIncidence of grade 3–4 treatment-related select AEs in all intervals with NIVO+IPI after 12 months was ≤1.6%. e≥40 mg prednisone daily or equivalent. Treatment-related AEs and treatment-related select AEs were calculated by 6-month interval using the total number of new events out of the total number of patients at risk at the beginning of the interval.
Figure 6 Safety outcomes over time. (A) Treatment-related adverse events (AEs) over time by 6-month interval with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN). (B) Select treatment-related AEs over time by 6-month interval with NIVO+IPI. (C) Corticosteroid use over time with NIVO+IPI. aN=patients at risk at the beginning of each 6-month interval, and patients may be counted more than once across intervals. bIncidence of grade 3–4 treatment-related AEs in all intervals with NIVO+IPI after 24 months was ≤2.4%. cN=patients at risk at the beginning of each 6-month interval, and patients may be counted more than once across intervals. dIncidence of grade 3–4 treatment-related select AEs in all intervals with NIVO+IPI after 12 months was ≤1.6%. e≥40 mg prednisone daily or equivalent. Treatment-related AEs and treatment-related select AEs were calculated by 6-month interval using the total number of new events out of the total number of patients at risk at the beginning of the interval.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 238

Metadata

Authors
Motzer, R. J., Escudier, B., McDermott, D. F., Arén Frontera, O., Melichar, B., Powles, T., Donskov, F., Plimack, E. R., Barthélémy, P., Hammers, H. J., George, S., Grünwald, V., Porta, C., Neiman, V., Ravaud, A., Choueiri, T. K., Rini, B. I., Salman, P., Kollmannsberger, C. K., Tykodi, S. S., Grimm, M.-O., Gurney, H., Leibowitz-Amit, R., Geertsen, P. F., Amin, A., Tomita, Y., McHenry, M. B., Saggi, S. S., & Tannir, N. M.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Institut Gustave Roussy (FR)
  • Beth Israel Deaconess Medical Center (US)
  • Centro de Investigación Clínica Bradford Hill, Santiago, Chile
  • University Hospital Olomouc (CZ)
  • National Health Service (GB)
  • Aarhus University Hospital (DK)
  • Fox Chase Cancer Center (US)
  • Institut de Cancérologie Strasbourg (FR)
  • The University of Texas Southwestern Medical Center (US)
  • Roswell Park Comprehensive Cancer Center (US)
  • Essen University Hospital (DE)
  • University of Pavia (IT)
  • Tel Aviv University (IL)
  • Centre Hospitalier Universitaire de Bordeaux (FR)
  • Dana-Farber Cancer Institute (US)
  • Cleveland Clinic (US)
  • Fundación Arturo López Pérez (CL)
  • BC Cancer Agency (CA)
  • University of Washington (US)
  • Jena University Hospital (DE)
  • Westmead Hospital (AU)
  • Oncology Institute, Shamir Medical Center, Be'er Yaakov, Israel
  • Herlev Hospital (DK)
  • Levine Cancer Institute (US)
  • Niigata University (JP)
  • Bristol-Myers Squibb (United States) (US)
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Motzer, Robert J
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2020-07
Volume
8
Issue
2
Pages
e000891
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3042095160
Cited by
224
References
18
Citations by year
2026: 6 · 2025: 15 · 2024: 27 · 2023: 43 · 2022: 57 · 2021: 58 · 2020: 18
FWCI
24.77
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
Funders
Bristol Myers Squibb and ONO Pharmaceutical Company Limited
Topics
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords
advanced renal cell carcinoma, nivolumab, ipilimumab, sunitinib, immune checkpoint inhibitors, first-line therapy, overall survival, progression-free survival, objective response rate, long-term follow-up, IMDC risk stratification, treatment safety, immune-related adverse events, CheckMate 214, combination immunotherapy, tyrosine kinase inhibitors
MeSH terms
Ipilimumab, Sunitinib, Nivolumab, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Female, Follow-Up Studies, Humans, Kidney Neoplasms, Male, Survival Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. https://app.cochat.ai/papers/10.1136/jitc-2020-000891
The paper
Motzer, R. J., Escudier, B., McDermott, D. F., Arén Frontera, O., Melichar, B., Powles, T., Donskov, F., Plimack, E. R., Barthélémy, P., Hammers, H. J., George, S., Grünwald, V., Porta, C., Neiman, V., Ravaud, A., Choueiri, T. K., Rini, B. I., Salman, P., Kollmannsberger, C. K., . . . Tannir, N. M. (2020). Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2020-000891

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.